Psychopharmacology

杂志介绍

Psychopharmacology杂志介绍

《Psychopharmacology》是一本以English为主的未开放获取国际优秀期刊，中文名称精神药理学，本刊主要出版、报道医学-NEUROSCIENCES领域的研究动态以及在该领域取得的各方面的经验和科研成果，介绍该领域有关本专业的最新进展，探讨行业发展的思路和方法，以促进学术信息交流，提高行业发展。该刊已被国际权威数据库SCIE收录，为该领域相关学科的发展起到了良好的推动作用，也得到了本专业人员的广泛认可。该刊最新影响因子为3.5，最新CiteScore 指数为7.1。

本刊近期中国学者发表的论文主要有：

• Desulfovibrio confers resilience to the comorbidity of pain and anxiety in a mouse model of chronic inflammatory pain

  Author: Wu, Zifeng; Liu, Hanyu; Yan, Enshi; Zhang, Xinying; Wang, Yuanyuan; Huang, Chaoli; He, Teng; Miao, Liying; Yang, Ling; Jiang, Riyue; Qi, Changyong; Liu, Cunming; Wang, Di; Yang, Chun

• The effects of serotonergic psychedelics in synaptic and intrinsic properties of neurons in layer II/III of the orbitofrontal cortex

  Author: Tang, Zi-Hang; Yu, Zhi-Peng; Li, Qiong; Zhang, Xiao-Qin; Muhetaer, Kadeliya; Wang, Zheng-Chun; Xu, Peng; Shen, Hao-Wei

• The M1 muscarinic acetylcholine receptor regulates the surface expression of the AMPA receptor subunit GluA2 via PICK1

  Author: Zhu, Zengyan; Wang, Wenjuan; Gu, Chao; Wang, Mei; Yan, Yinghui

• Chronic restraint stress-induced depression-like behavior is mediated by upregulation of melanopsin expression in C57BL/6 mice retina

  Author: Fu, Yingmei; Liu, Shanshan; Dong, Yigang; Gan, Yixia; Guo, Xiaoyun; Liu, Hongmei; Xu, Qingqing; Yuan, Ruixue; Ning, Ailing; Hong, Wu; Peng, Yanmin; Yu, Shunying

英文介绍

Psychopharmacology杂志英文介绍

Official Journal of the European Behavioural Pharmacology Society (EBPS)

Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:

Human Psychopharmacology: Experimental

This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.

Human Psychopharmacology: Clinical and Translational

This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.

Preclinical psychopharmacology: Behavioral and Neural

This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.

Preclinical Psychopharmacology: Translational

This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.

Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic

This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.